#161765

OV-90 cell line

Cat. #161765

OV-90 cell line

Cat. #: 161765

Organism: Human

Tissue: Derived from malignant ascites of a chemonaive ovarian cancer patient

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Provencher et al. 2000. In Vitro Cell.Dev.Biol.-Animal (36): 357–361. PMID:10949994

Tool Details
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: OV-90 cell line
  • Alternate name: OV-90
  • Organism: Human
  • Gender: Female
  • Tissue: Derived from malignant ascites of a chemonaive ovarian cancer patient
  • Donor: Grade 3 – Stage IV; Mutations: TP53 Exon 6, CDKN2A Exon 2; Pre-treatment
  • Crispr: No
  • Receptors of note: No
  • Description: Tumorigenic epithelial ovarian cancer cell line derived from malignant ascites of a patient never exposed to chemotherapy or radiation therapy. Cell line retains cahracteristics of the original epithelial ovarian cancers from which it was derived.

References

  • Raspaglio et al. 2023. Cancers (Basel). 18
  • 15(8):2361. PMID: 37190289 Yee et al. 2022. Front Bioeng Biotechnol. 10
  • 10:836984. PMID: 35223797 Brodeur et al. 2021. Sci Rep. 14
  • 11(1):18183. PMID: 34521878 Buttarelli et al. 2022. J Exp Clin Cancer Res. 4
  • 41(1):50. PMID: 35120576